Geneva Partners’s Pfizer PFE Stock Holding History

Geneva Partners’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-19,555	Closed	-$788K	–	70
2019 Q1	$788K	Sell	19,555 -1,146	-6%	-$45.9K	0.67%	47
2018 Q4	$857K	Buy	20,701 +9,145	+79%	+$380K	0.99%	35
2018 Q3	$483K	Buy	+11,556	New	+$445K	0.37%	66

Other funds holding PFE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geneva Partners's PFE Position: Q2 2019 in Review

Geneva Partners sold out of Pfizer (PFE) in Q2 2019, closing a stake of 19,555 shares — an estimated $788K sold.

Geneva Partners first reported a position in PFE in Q3 2018 and held it in 3 quarters. The position peaked at $857K in Q4 2018. 2,378 funds tracked by Wall St. Rank hold PFE as of Q2 2019.

Geneva Partners reported no remaining Pfizer position as of Q2 2019 after selling out during the quarter.
Geneva Partners sold 19,555 Pfizer shares in Q2 2019, an estimated $788K.
Geneva Partners first reported a position in Pfizer in Q3 2018 and held it in 3 quarters.
Geneva Partners's Pfizer position peaked at $857K in Q4 2018.
2,378 funds tracked by Wall St. Rank held Pfizer as of Q2 2019.

Based on Geneva Partners's 13F filing for Q2 2019, filed 31 Jul 2019.